On March 23, 2026, Telomir Pharmaceuticals, Inc. held its Annual Meeting of Shareholders, where significant amendments were approved regarding the company's 2023 Omnibus Incentive Plan and Bylaws. The shareholders voted to increase the number of shares reserved under the Plan from 6,500,000 to 11,500,000, allowing for a greater incentive structure for employees and executives. Additionally, the amendment to the Bylaws reduced the quorum requirement for shareholder actions from a majority to one-third, facilitating easier decision-making processes in future meetings. The meeting also saw the election of four new directors: Erez Aminov, Matthew Whalen, Edward MacPherson, and Matthew Del Giudice, M.D., who will serve until the next Annual Meeting. The voting results indicated strong support for these proposals, with over 51% of shares represented at the meeting. The approval of these changes is expected to positively impact the company's operational flexibility and governance structure, potentially enhancing shareholder value in the long term.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.